Posts Tagged ‘warning’

Paxil and Prozac Linked to Risk of Heart Birth Defects

Monday, June 27th, 2011

AboutLawSuits.com – June 27, 2011

According to Finnish researchers, doctors should avoid prescribing Paxil or Prozac to pregnant women, due to the potential risk of heart birth defects.

In a study published in Obstetrics & Gynecology medical journal, researchers found that side effects of Prozac and Paxil use during pregnancy may increase the risk of women giving birth to children with congenital heart defects. Both drugs belong to a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs).

Researchers looked at national data from Finland on 635,583 births occurring between 1996 and 2006, and found that 31 out of every 10,000 women who took Paxil during pregnancy gave birth to children with right ventricular outflow tract defects that affect blood flow from the right chambers of the heart to the rest of the body, more than four times the frequency of births among women who did not take Paxil. For those who took Prozac, 105 babies born out of every 10,000 had isolated ventrical septal defects; a hole between the left and right sides of the heart, which was more than double the rate of babies born to women who did not take the drug.

The researchers also found that women who took any SSRI antidepressant during pregnancy were more than twice as likely to give birth to a child with a neural tube defect; 22 out of every 10,000 newborns, as compared to 9 out of every 10,000 newborns born to women who did not take any SSRI during pregnancy.

SSRIs are a relatively new class of antidepressants, which help reduce symptoms of depression by preventing certain nerve cells in the brain from re-absorbing the chemical serotonin. These drugs are commonly used by millions of Americans with depression.

Although the drugs have been found to cause fewer side effects than older anti-depressants, research has shown that users of the drugs could also face an increased risk of suicides, and use during pregnancy has been linked to a risk of birth defects, especially among users of Paxil.

Prozac (fluoxetine) is marketed by Eli Lilly and is approved for the treatment of depression, obsessive-compulsive disorder (OCD) and other psychiatric problems. In 2007 there were more than 22 million Prozac prescriptions in the United States.

Paxil (paroxetine) is a selective serotonin reuptake inhibitor prescribed to treat depression. Approved in 1992, it has become one of the most commonly prescribed drugs in the United States, with sales of just under $1 billion in 2008.

In December 2005, the FDA issued an alert about the risk of birth defects from Paxil after studies showed the drug could increase the risk of the heart defects when taken during the first three months of pregnancy. At that time, the agency also required GlaxoSmithKline to update the warning label to include information about the risk of birth defects from Paxil side effects.

The company reportedly agreed to settle hundreds of Paxil heart birth defect lawsuits last year. The Paxil lawsuits were filed by parents who say that the use of the antidepressant during pregnancy caused persistent pulmonary hypertension in newborns (PPHN) and other birth defects. The lawsuits claimed that the company failed to warn consumers and doctors that use of Paxil during pregnancy could lead to congenital heart defects in newborns. The lawsuits also claimed that the company purposefully hid test results that would have revealed the side effects of Paxil and misled doctors.

http://www.aboutlawsuits.com/paxil-prozac-birth-defect-study-19139/

« Return to news items


Share

Antipsychotic Drugs Deadly for Elderly Patients, Prescribed Anyway

Thursday, May 12th, 2011

ThirdAge.com

by Alex Heig

Antipsychotic drugs prescribed to as many as one in seven patients with dementia at nursing homes increase the risk of death and are not approved for such uses, a government audit has found.

Drugs such as Risperdal, Zyprexa, Seroquel, Abilify and Geodon are “potentially lethal” to many of the patients getting them and in many cases, completely unnecessary and unneeded.

The Centers for Medicare and Medicaid Services said that some of the inappropriate use of antipsychotics can be attributed to drugmakers’ habit of paying kickbacks to nursing homes to increase prescriptions for the medicines.

Medicare officials said that diagnosis information is for the most part omitted from prescriptions so officials are unable to tell whether the prescription is appropriate.

The Food and Drug Administration has warned doctors of the risk of using antipsychotic drugs in elderly dementia patients, but doctors have continued the practice because of a relative lack of other options.

Doctors want to maximize quality of life by treating the patient’s agitation even if that means the patient will die a bit sooner,” said Dr. Daniel J. Carlat, editor-in-chief of The Carlat Psychiatry Report, a medical education newsletter for psychiatrists.

The results of the government audit showed that during the first six months of 2007, 304,983 elderly patients in nursing homes (out of 2.1 million total) had at least one Medicare claim for an antipsychotic medicine.

Meanwhile, 83 percent of antipsychotic prescriptions for elderly nursing home residents were for uses not approved by federal drug regulators, and 88 percent were to treat patients with dementia, for whom the drugs can be lethal.

Federal regulations prohibit any drug paid for by the government from being used for non-approved reasons. Auditors found that 51 percent of claims for antipsychotic medication violated this rule.

Additionally, the government bans drugs used in excessive duration or dose level, even for patients that qualify. Auditors found that 22 percent of claims failed to live up to this requirement.

http://www.thirdage.com/news/antipsychotic-drugs-deadly-for-elderly-patients-prescribed-anyway_05-10-2011?page=1

« Return to news items


Share

New study finds Anti-seizure drugs, increasingly prescribed for people labeled “bipolar,” induce suicide & death

Tuesday, August 31st, 2010

Natural News
By David Gutierrez
August 31, 2010

Popular anti-seizure drugs may seriously increase a patient’s risk of suicide and violent death, according to a study conducted by researchers from Brigham and Women’s Hospital and Harvard Medical School, and published in the Journal of the American Medical Association.

The drugs, known as anticonvulsants, were initially designed for the treatment of epilepsy but are now widely prescribed “off-label” for conditions such as bipolar disorder, migraine headaches and pain.

“We all know the range of uses of these medications is very, very wide,” researcher Elisabetta Patorno said.

The researchers examined the prescription and medical records of more than 300,000 people above the age of 14 who had been prescribed an anticonvulsant for the first time between July 2001 and December 2006.

All of the drugs, they found, significantly increased a patient’s risk of attempted or successful suicide, as well as violent death by other causes. During the course of the study, there were 801 attempted suicides, 26 successful suicides and 41 violent deaths.

“We found increased risk for suicidal acts beginning within the first 14 days after treatment initiation, opening the possibility that anticonvulsant medications could induce behavioral effects prior to the achievement of their full therapeutic effectiveness,” the researchers wrote.

Based on prior studies, the FDA ruled in 2008 that all anticonvulsants must carry labels warning that they double the risk of suicidal thoughts and actions. These older studies had not been able to determine if any drugs posed higher risks than others, however.

Read entire article here:  http://www.naturalnews.com/029614_suicide_anti-seizure_drugs.html

« Return to news items


Share

Toronto Sun—“The girl with every reason to live” Parents blame daughter’s suicide on antidepressant Paxil

Saturday, June 12th, 2010

Toronto Sun
By Michelle Mandel
June 12, 2010

Sara Carlin had everything to live for: She was smart, athletic, beautiful and pursuing her dream of becoming a doctor.

But on May 6, 2007, that bright future ended abruptly with a piece of electrical wire.

The promising 18-year-old had hung herself in her family’s Oakville basement and her grieving parents blame her suicide on the Paxil antidepressant she’d been prescribed more than a year before.

In emotional testimony that left many fighting back tears, Sara’s mother Rhonda told a coroner’s inquest that her daughter earned 90’s in school, played baseball and women’s hockey, held a part-time job at an optometrist’s office and tutored other kids in math.

“She was a pretty exceptional girl, she was absolutely loving and she was beautiful,” her mom proudly recalled Wednesday before the presiding coroner, Dr. Bert Lauwers. “She really was an exceptional daughter.”

But in the early part of 2006, Sara began to change. During the family’s March break vacation to Palm Springs, she wouldn’t get out of bed most days and got drunk at dinner. “It was so unlike her,” her mom said.

It was only later that she learned Sara had complained of anxiety and depression to her family doctor and had recently been prescribed Paxil, one of the antidepressants known as selective serotonin reuptake inhibitors (SSRIs).

“I said, ‘Why on earth, Sara would you be on antidepressants?’ I was astounded,” she recalled for the five-member jury. “Why, why would he be giving these to her? This was a wonderful, happy girl.”

While Sara lost her much older brother to a drug overdose in 2000, her mother believed her daughter had coped well with his death and never wanted the counselling she’d been offered.

So this need for antidepressants, she said, came out of the blue.

“She was very troubled, much more troubled than any of us knew,” her mother acknowledged.

While her parents repeatedly voiced their reservations about Paxil, Sara brushed them off, saying her doctor told her it would make her feel better. “I didn’t even know the horrific side effects of Paxil at that time,” her mom said. “I certainly didn’t know what I know now.”

Health Canada issued warnings in 2003 and 2004 that prescribing antidepressants to teens could lead to behavioural or emotional changes that might put them at increased risk of suicidal behaviour.

Read entire article:  http://www.torontosun.com/news/columnists/michele_mandel/2010/06/10/14340951.html

« Return to news items


Share

Psychiatry & the United States of Affliction: Are You Normal or Finally Diagnosed?

Wednesday, June 9th, 2010

The Diagnostic and Statistical Manual of Mental Disorders is a list that can be abused to the detriment of patients and benefit of drug companies.

Miller-McCune
By Arnie Cooper
June 8, 2010

“My dear Sir, take any road, you can’t go amiss. The whole state is one vast insane asylum.” — James L. Petigru

Spend just a few minutes watching prime time television with its endless pageant of commercials for antidepressants and anti-anxiety meds and you start to wonder if USA really means the United States of Affliction.

Such “direct to consumer” drug advertising ties into one of the most far-reaching criticisms in revising the Diagnostic and Statistical Manual of Mental Disorders: the potential to transform normal human behavior into a mental disorder.

This issue didn’t arise with the ongoing revision of the DMS-V. It’s long been a concern for psychiatry, which must exist uneasily alongside pharmaceutical companies’ hopes of expanding their markets and Americans’ desire for take-a-pill quick fixes. But past experiences suggest new diagnoses will reap a harvest of not fully intended consequences of patients larded with labels — and prescriptions.

Christopher Lane, an intellectual historian who has written extensively on psychiatry and culture, detailed the inclusion of “social anxiety disorder” in the DSM-III in his 2007 book, Shyness: How Normal Behavior Became a Sickness.

Lane revealed how the 15-member DSM-III task force, in its quest to establish psychiatry as a legitimate science (and riding the wave of drug companies looking to expand their markets for anti-psychotics and tranquilizers), spit out “almost over night” various new disorders, including one for those uncomfortable with social situations.

No longer need shyness be a variant of normal. Now it can be a neurochemical disorder addressable with GlaxoSmithKline’s multibillion-dollar marvel Paxil. Before safety concerns and patent expirations raised their ugly heads, antidepressants had become the second-largest selling class of drugs in the United States.

“In this desire to biologize and medicalize, with the idea that every personal crisis or problem is due to a disorder of the brain, we’ve lost sight of the vast complexity of behavioral responses to external stresses,” Lane says. Add to that some possibly dangerous side effects. Along with Prozac and Zoloft, Paxil was found to increase thoughts of suicide, especially among teens, prompting an FDA warning in 2004.

Read entire article:  http://www.miller-mccune.com/health/are-you-normal-or-finally-diagnosed-17073/

« Return to news items


Share

FDA says Pfizer overdosed 13 children in antipsychotic drug trial

Tuesday, April 20th, 2010

Reuters
April 20, 2010

U.S. health regulators have warned Pfizer Inc. over a series of failures that led to the overdosing of at least 13 children in a clinical trial of its antipsychotic drug Geodon, according to a letter made public on Tuesday.

The FDA, in an April 9 warning letter to the world’s largest drugmaker, said Pfizer “failed to ensure proper monitoring of the investigation” for a product.

The agency did not name the drug in the public version of the letter, but Pfizer confirmed it related to the use of Geodon in children with bipolar disorder.

It said the company did not properly monitor the study and, “as a result of inadequate monitoring, widespread overdosing of study subjects at multiple study sites was neither detected nor corrected in a timely manner.”

Several children given overdoses experienced tremors, restless legs and other complications, the letter said.

Pfizer recognizes the issue’s seriousness and is committed to addressing the concerns, it said. Pfizer reported many items cited in the letter as many as four years ago, it said.

Since then it “has instituted several new measures designed to improve monitoring and execution of clinical trials, including our oversight of clinical investigators,” it said.

Read entire article:  http://www.reuters.com/article/idUSTRE63J4XQ20100420

« Return to news items


Share

Killing You with Drugs: Legally—Pharma’s attempts to bury increasing # of studies linking psychiatric drugs to suicide

Thursday, April 15th, 2010

The Market Oracle
By Michael Stathis
April 15, 2010

Is there any reason why Pfizer shares are down today?

Just yesterday, shares were trading at ~ $17.30. Today, with the DJIA up by 0.7%, Pfizer is down by nearly 1%.

A clue to this sell-off MIGHT be due to the anticipation by investors of increasing pressure to change the way drugs are prescribed. This could also trigger several lawsuits down the road.

Recently, another study was published in the Journal of the American Medical Association discussing elevated suicide risks associated with the use of anticonvulsant drugs. Anticonvulsants have been approved by the FDA for people diagnosed with epilepsy.

Of course, this is not the first study showing anticonvulsants raised the risk of suicide.

In 2008, the FDA required all anticonvulsant drugs to have a warning label that disclosed a two-fold increased risk of suicide. However, warning labels are rarely effective. They simply enable drug companies to continue to sell what many experts feel to be dangerous drugs, while having the safeguard of a disclaimer.

When patients receive a prescription for a drug to address a medical condition, they assume it’s a safe drug; otherwise, it wouldn’t be approved for use. And their doctor certainly wouldn’t prescribe it if it weren’t safe, would he?

According to DEA and FDA regulations, physicians are free to prescribe any drug for any condition they see fit, known as off-label use. As a result of off-label usage, anticonvulsants are prescribed for many different medical conditions like bipolar disorder, pain and migraine headaches. As you might imagine, in some cases, off-label use has accounted for a big chunk of drug sales.

The class of drugs prescribed most by physicians for off-label uses are the antipsychotics (Prozac, Xanax, Zyprexa, etc). The FDA has approved these drugs to treat a variety of neurologic conditions such as depression and bipolar disease. However, drug companies have used many methods to get physicians to prescribe them for a wide range of off-label uses.

Read entire article:  http://www.marketoracle.co.uk/Article18652.html

« Return to news items


Share